Healthy volunteers test new nerandomilast formulation and food effects

NCT ID NCT06624072

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial enrolled 15 healthy adults to compare two different formulations of the drug nerandomilast and to see if food affects how the new formulation is absorbed. Participants received single doses in a crossover design. The study focuses on drug levels in the blood, not on treating any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nerandomilast (also known as BI 1015550, JASCAYD®)
What this could lead to: If successful, this study could help determine the best formulation and dosing instructions for nerandomilast, potentially improving how it is taken in future trials.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only measures how the drug moves through the body, not whether it works for any disease. Results may not predict real-world effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

Humanpharmakologisches Zentrum Biberach

Biberach, 88397, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.